Log in to search using one of your social media accounts:

 

Evaluation of the impact of renal failure on correlation and concordance between two free light chain assays
Measurement of serum free light chains (FLC) is recommended for diagnosis of monoclonal gammopathies. FLC measurements with FreeliteTM (Binding Site) and N-Latex FLC (Siemens) assays were performed on 1215 fresh sera from patients with or without monoclonal gammopathy and renal failure. A good correlation was demonstrated between both assays, but it remained 7.6%-20.8% discordances between the methods related to the FLC-ratio interpretation. In patient ’s follow-up, few discrepancies were observed. Neither of the assays performed better than the other: they provide comparable but not equivalent results, and discrepan...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Caroline Moreau, Brice Autier, Thibault Cavey, Emmanuel Rouger, James Norwood, Claude Bendavid, Martine Escoffre, Martine S ébillot, Olivier Decaux Tags: Original Study Source Type: research

Survival rates of adults with acute lymphoblastic leukemia in a low- income population. A decade of experience at a single institution in M éxico
Adult acute lymphoblastic leukemia has an elevated mortality rate, with little improvement in recent decades. 94 patients treated over ten years in a low-income population were studied. Younger age, elevated high-risk disease and high relapse rate were documented. However, overall survival after complete remission was the same as in industrialized countries. Cure threshold with current treatment approaches has been reached. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Jos é Carlos Jaime-Pérez, Raúl Alberto Jiménez-Castillo, José Luis Herrera-Garza, Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer Tags: Original Study Source Type: research

Single-Center Series of Bone-Marrow Biopsy-Defined Large Granular Lymphocyte leukemia; high rates of sustained response to oral methotrexate
39 patients were stringently diagnosed with large granular lymphocyte leukemia. 15 (38%) remain untreated, 13/24 initially treated with prednisolone, overall response rate (ORR) 84.6%, median duration of response (DOR) 13.5 months, 9/24 received oral methotrexate ORR 89%, median DOR 132.7 months. Five received methotrexate following prednisolone failure; all responded. Single agent oral methotrexate results in long responses with minimal toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Talha Munir, Mark J. Bishton, Ian Carter, Andrew McMillan, Simon O ’Connor, Vishakha Sovani, Andrew P. Haynes, Christopher P. Fox Tags: Original Study Source Type: research

Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia
Microabstract: The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival. The favorable risk cohort had better relapse-free survival and overall survival as compared to the outcomes of patients in the intermediate and adverse risk cohorts; the relapse-free survival and overall survival did not differ between intermediate and adverse cohorts. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O ’Brien, Hagop Kantarjian, Farhad Ravandi Tags: Original Study Source Type: research

Aberrant p15, p16, p53 and DAPK gene methylation in myelomagenesis: clinical and prognostic implications
Microabstract: Aberrant DNA methylation is important in multiple myeloma pathogenesis. Methylation of p15, p16, p53 and DAPK genes was evaluated in bone marrow (94 patients; 8 controls) by methylation-specific polymerase chain reaction. 63% of MM and 39% of MGUS presented ≥1 hypermethylated gene (p (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Catarina Geraldes, Ana Cristina Gon çalves, Emília Cortesão, Marta Isabel Pereira, Adriana Roque, Artur Paiva, Letícia Ribeiro, José Manuel Nascimento-Costa, Ana Bela Sarmento-Ribeiro Tags: Original Study Source Type: research

Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Transfusional iron overload remains a serious problem in alloHSCT setting. Liver is among the most common organs that iron accumulate. The degree of hepatic iron content might be associated with poorer survival in alloHSCT recipients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Serdar Sivgin, Suleyman Baldane, Kemal Deniz, Gokmen Zararsiz, Leylagul Kaynar, Mustafa Cetin, Ali Unal, Bulent Eser Tags: SOHO Supplement 2016 Source Type: research

The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload
Transfusional iron overload (IO) is considered to be a significant problem hematopoietic stem cell transplantation (HSCT) recipients. Patients with IO have poorer outcomes compared to those with normal iron stores. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Serdar Sivgin, Mehmet Fatih Karamustafaoglu, Esra Yildizhan, Gokmen Zararsiz, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, Ali Unal Tags: SOHO Supplement 2016 Source Type: research

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Dose intensification of chemotherapy and the combination of a third cytotoxic agent with standard cytarabine and anthracycline-based induction chemotherapy have led to improved outcomes in select groups of patients with acute myeloid leukemia (AML). However, despite some progress in this area, it appears that we might be reaching the limit of cytotoxic chemotherapy for the treatment of AML, especially in older patients and in those with poor-risk features whose disease tends to be relatively chemoresistant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Nicholas J. Short, Farhad Ravandi Tags: SOHO Supplement 2016 Source Type: research

When to Consider Allogeneic Transplantation in CML
Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Jerald Radich Tags: SOHO Supplement 2016 Source Type: research

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
In a phase I dose-escalation study using eltrombopag to treat patients with myelodysplastic syndromes after hypomethylating agents failure, we observed that patients with chronic myelomonocytic leukemia may respond to eltrombopag. However, use in a subset of chronic myelomonocytic leukemia patients may be limited owing to leukocytosis and circulating blasts. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Hanadi Ramadan, Vu H. Duong, Najla Al Ali, Eric Padron, Ling Zhang, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji Tags: SOHO Supplement 2016 Source Type: research

Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States
We report our experience with adult T-cell leukemia/lymphoma, a rare and aggressive form of T-cell lymphoma, highlighting the clinical characteristics, response to therapy, and outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Christa Roe, Rami Komrokji, Ling Zhang, Samantha Price, Lubomir Sokol Tags: SOHO Supplement 2016 Source Type: research

Is Maintenance Therapy for Everyone?
Although myeloma remains an incurable disease among majority of myeloma patients, the prognosis has significantly improved after the introduction of novel agents. While more agents are being explored for their anti-myeloma activity, the more familiar agents with a better tolerability profile have been tested in the maintenance arena. Lenalidomide and bortezomib so far have shown promise as effective maintenance agents in prolonging PFS, and also OS in some studies. The current review aims at describing the clinical data supporting various maintenance therapies and also at providing some clarity to a few concerns associated...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Ajay K. Nooka, Sagar Lonial Tags: SOHO Supplement 2016 Source Type: research

Trends in Clinical Investigation for Myelodysplastic Syndromes
Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are available, and there are many open questions on how to select the most adapted agent and/or sequence of agents in a specific individual. (Sou...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Thomas Prebet, Amer Zeidan Tags: SOHO Supplement 2016 Source Type: research

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
The treatment of patients with chronic lymphocytic leukemia (CLL) whose tumor presents the del(17p)/TP53 mutation is a major challenge. Treatment with chemo(immuno)therapy, immunomodulators, or the anti-CD52 monoclonal antibody alemtuzumab produces transient, unsatisfactory responses. Reduced-intensity-conditioning allotransplantation produces sustained progression-free survival and overall survival (40%-60% at 5 years), equivalent to the cure of the disease, even in cases with adverse biomarkers. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Emili Montserrat, Peter Dreger Tags: SOHO Supplement 2016 Source Type: research

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma
Discovering prognostic factors that simultaneously describe tumor characteristics and improve risk stratification is a priority in cutaneous T-cell lymphoma (CTCL). More than a third of advanced stage CTCL patients in this cohort had detectable cell free plasma Epstein –Barr virus (EBV)-DNA (pEBVd) using quantitative real-time polymerase chain reaction. An increased level of pEBVd was highly concordant with EBV (ie, Epstein–Barr virus RNAs) in tumor tissue and was associated with inferior survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Bradley M. Haverkos, Alejandro A. Gru, Susan M. Geyer, Anissa K. Bingman, Jessica A. Hemminger, Anjali Mishra, Henry K. Wong, Preeti Pancholi, Aharon G. Freud, Michael A. Caligiuri, Robert A. Baiocchi, Pierluigi Porcu Tags: SOHO Supplement 2016 Source Type: research

How to Think About Risk in Myeloma
An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for induction and maintenance. Future approaches are expected to involve drugs that are “risk agnostic,” such as monoclonal antibodies and immunotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Amrita Krishnan Tags: SOHO Supplement 2016 Source Type: research

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape of MPN-BP is distinct from de novo acute myeloid leukemia and offers insight into molecular mechanisms contributing to clonal evolution providing potential novel drug targets. A number of retrospective studies have identified patient- and disease-specific variables associated with increased risk of leukemic transformation (LT) of an underlying MPN. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: John Mascarenhas Tags: SOHO Supplement 2016 Source Type: research

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Immunosuppresive therapy in low risk myelodysplastic syndrome can achieve sustained hematologic improvement but is underutilized due to lack of selection criteria. We completed a retrospective analysis of sixty-six patients treated with immunosuppressive therapy to investigate treatment outcome and clinical co-variables that influence response. Overall hematologic improvement was 42%, comparable to other treatment options for lower risk MDS. The response rate was higher in low risk disease, treated early on in the disease process with immunosuppressive therapy as the first line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Mintallah Haider, Najla Al Ali, Eric Padron, Pearlie Epling-Burnette, Jeffrey Lancet, Alan List, Rami Komrokji Tags: SOHO Supplement 2016 Source Type: research

Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience
Primary effusion lymphoma (PEL) is a rare form of lymphoma, primarily seen in individuals who are immunosuppressed. We studied all cases of PEL seen at our institution over a 15-year period and observed that if affected mostly male patients with HIV who were not taking the antiretroviral medication. Newer chemotherapy regimens including the drug bortezomib may be more effective in treating PEL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Arjun Gupta, Shiraj Sen, Eileen Marley, Weina Chen, Harris V. Naina Tags: SOHO Supplement 2016 Source Type: research

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes
The higher risk myelodysplastic syndrome (MDS) patients, defined by the International Prognostic Scoring System (IPSS) as intermediate-2 or high-risk groups, compromise a third of MDS patients who have an expected survival of less than 1.5 years. Our ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations. Allogeneic hematopoietic stem-cell transplantation (AHSCT) remains the only curative option. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Rami S. Komrokji Tags: SOHO Supplement 2016 Source Type: research

Successful Nonsurgical Eradication of Invasive Gastric Mucormycosis
We present the case of successful nonsurgical eradication of gastric mucormycosis with combined polyene and azole antifungal agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Georges El Hachem, Nabil Chamseddine, Ghada Saidy, Camil Choueiry, Claude Afif Tags: SOHO Supplement 2016 Source Type: research

Bone Marrow Necrosis: An Unusual Initial Presentation of Sickle Cell Anemia
A 25-year-old woman, previously healthy, was referred to our hospital for management of anemia and thrombocytopenia, with a working diagnosis of thrombotic thrombocytopenic purpura. Two weeks before her presentation to us, she had undergone a cesarian section after failure to progress in labor. No complications developed after the delivery, and she had not received any blood transfusions. One week later, she developed a high-grade fever without any localizing symptoms. She was prescribed antipyretics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Georges El Hachem, Nabil Chamseddine Tags: SOHO Supplement 2016 Source Type: research

Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience
Little is known regarding myelodysplastic syndromes (MDS) in the younger population. This retrospective review reviewed the characteristics, outcomes, and response to treatment in the adolescent and young adult (AYA) population compared to an older population. MDS was found to be rare and more aggressive in AYA. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Joanna Grabska, Bijal Shah, Damon Reed, Najla Al Ali, Eric Padron, Hanadi Ramadan, Jeffrey Lancet, Alan List, Rami Komrokji Tags: SOHO Supplement 2016 Source Type: research

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an older population, age-associated comorbidities can preclude patients from cure. HSCT is associated with the risk of morbidity and mortality; however, with safer conditioning regimens and improved supportive care, eligible patients with an appropriately matched donor can receive this therapy without exclusion by older age alone. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Asmita Mishra, Claudio Anasetti Tags: SOHO Supplement 2016 Source Type: research

Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature
In this study we present the general characteristics in a single institution. Treatment with rituximab based-chemotherapy was effective with long term responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Julio C. Chavez, Jose Sandoval-Sus, Pedro Horna, Samir Dalia, Celeste Bello, Paul Chevernick, Eduardo M. Sotomayor, Lubomir Sokol, Bijal Shah Tags: SOHO Supplement 2016 Source Type: research

Clonal Evolution in Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy encountered among patients in the United States. The last decade has seen incremental improvements in the survival of patients with MM. These advances are, to a large extent, attributable to the addition of proteasome inhibitors and immunomodulatory drugs to the armamentarium of treatment options. The adoption of these drug classes was the result of an empiric research paradigm. However, with the application of next generation sequencing technologies, we are now starting to unravel the genomic landscape of MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Bita Fakhri, Ravi Vij Tags: SOHO Supplement 2016 Source Type: research

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
PDE4 expression control the inflammation which has an essential role in the pathogenesis of myelodysplastic syndromes (MDS). The expression of each isoform of the PDE4 was evaluated, using transcriptomic profiling, from healthy individuals (n = 10) and patients with MDS (n = 24) or chronic myelomonocytic leukemia (n = 19). PDE4 mean expression was generally higher in MDS than in healthy individuals. Higher PDE4 expression seemed to have a possible negative effect on survival and response to hypomethylating agent (P> .05). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Ali N. Chamseddine, Monica Cabrero, Yue Wei, Irene Ganan-Gomez, Simona Colla, Koichi Takahashi, Hui Yang, Zachary S. Bohannan, Guillermo Garcia-Manero Tags: SOHO Supplement 2016 Source Type: research

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia
We assessed patients with chronic myelogenous leukemia for serum Ca, PO4, bone alkaline phosphatase, N-telopeptide, osteoprotegerin levels and trabecular bone (TBA) in bone marrow (BM) specimens before and after treatment with dasatinib. We identified a significant increase in TBA % in post-dasatinib BM (P = .022). This suggests that dasatinib therapy can increase TBA, without significant changes in bone and mineral metabolism. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Daniela Hoehn, Jorge E. Cortes, L. Jeffrey Medeiros, Elias J. Jabbour, Juliana E. Hidalgo, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos Tags: SOHO Supplement 2016 Source Type: research

Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome –Positive Chronic Myeloid Leukemia
The overall prognosis of Philadelphia chromosome –positive chronic myeloid leukemia patients is today considered to be good thanks to targeted therapy with tyrosin kinase inhibitors (TKIs). A study of a 86-patient cohort showed a strong association between imatinib intolerance and blastic phase development, opening the question if whether it is perhaps due to a more aggressive form of the disease intrinsically resistant to TKIs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Jorge Luis Ángeles-Velázquez, Rafael Hurtado-Monroy, Pablo Vargas-Viveros, Silvia Carrillo-Muñoz, Myrna Candelaria-Hernández Tags: SOHO Supplement 2016 Source Type: research

How to Treat Essential Thrombocythemia and Polycythemia Vera
Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive therapy. The European LeukemiaNet has developed a series of management recommendations for front-line and second-line therapy to provide the optimal treatment...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Carlos Besses, Alberto Alvarez-Larr án Tags: SOHO Supplement 2016 Source Type: research

Perspectives and Future Directions for Acute Lymphoblastic Leukemia
I will begin with a patient case to highlight some of the major points I will be making. The patient was a 22-year-old man with relapsed precursor B (pre-B) acute lymphoblastic leukemia (ALL) who had presented to my clinic for possible participation in clinical trial S1312: a phase I trial of inotuzumab combined with CVP (cyclophosphamide, vincristine, prednisone). He was diagnosed in July 2012. At that time, fluorescence in situ hybridization studies demonstrated deletion of the Ikaros gene. He was treated with the pediatric-based regimen, C10403. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Anjali S. Advani Tags: SOHO Supplement 2016 Source Type: research

Prognosis of Primary Myelofibrosis in the Genomic Era
Currently, prognostication in primary myelofibrosis (PMF) relies on the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus, which incorporate age, blood counts, constitutional symptoms, circulating blasts, red cell transfusion need, and karyotype. Although the JAK2 V617F mutation was discovered a decade ago and MPL mutations shortly thereafter, it was the recent discovery of CALR mutations in the vast majority of JAK2/MPL-unmutated patients and recognition of the powerful impact of CALR mutations and triple-negative (JAK2/MPL/CALR-negative) status on outcome that set the stage for revision...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Prithviraj Bose, Srdan Verstovsek Tags: SOHO Supplement 2016 Source Type: research

Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia
ALL is the most common childhood malignancy and identification of prognostic factors is important for further improvement of the treatment outcome in this fatal disease. Cytogenetic changes and MRD are the most powerful prognostic factors in ALL. We identified significant correlations between some CD markers and cytogenetic subgroups which can be used in MRD monitoring and as potential therapy targets. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Shady Adnan Awad, Mahmoud M. Kamel, Mahmoud A. Ayoub, Ahmed M. Kamel, Essam H. Elnoshokaty, Niveen El Hifnawi Tags: SOHO Supplement 2016 Source Type: research

Editorial Board/Masthead
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Source Type: research

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology
The Society of Hematologic Oncology (SOHO) is an international society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO's mission is to promote worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Alan F. List, Hagop Kantarjian, Emil J. Freireich Tags: Editorial Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 25, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 25, 2016 Category: Hematology Source Type: research

FLT3 Inhibitors for Treating Acute Myeloid Leukemia
FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed several years ago and include midostaurin, lestaurtinib, sunitinib, and sorafenib. They are relatively nonspecific for FLT3, with other potential targets that include platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and Janus kinase 2. The second-generation inhibitors, including quizartinib, crenolanib, PLX3397, and ASP2215, are more potent and selective than the first-generation inhibitors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 23, 2016 Category: Hematology Authors: Mona Hassanein, Muhamad H. Almahayni, Syed O. Ahmed, Sameh Gaballa, Riad El Fakih Tags: Review Source Type: research

FLT3 inhibitors for treating Acute Myeloid Leukemia
Acute myelogenous leukemia (AML) is a clonal disorder of hematopoietic stem cells caused by acquired and occasionally inherited genetic alterations(1). FLT3 is a tyrosine kinase receptor that plays a role in proliferation and differentiation of hematopoietic stem cells. Constitutive activation of FLT3 by internal tandem duplication (ITD) mutation is a common molecular alteration in AML, occurring in approximately 20% to 30% of AML patients who have a comparatively poor clinical outcome and increased relapse rate(2). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 23, 2016 Category: Hematology Authors: Mona Hassanein, Muhamad H. Almahayni, Sameh Gaballa, Syed O. Ahmed, Riad El Fakih Tags: Review Article Source Type: research

Nonadherent Spheres With Multiple Myeloma Surface Markers Contain Cells that Contribute to Sphere Formation and Are Capable of Internalizing Extracellular Double-Stranded DNA
We present phenotypic analysis of free-floating spheres derived from the bone marrow clonogenic aspirate of a multiple myeloma patient. Besides CD73/CD20+/CD45+/CD19dim B cells, these spheres encompass a special subpopulation of cells that can natively internalize extracellular double-stranded DNA and that contribute to the colony assembly. Various cell types found in the free-floating spheres communicate with each other by secreting distinct sets of cytokines. These spheres are capable of forming xenotransplants upon grafting to immunodeficient NOD/SCID mice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 22, 2016 Category: Hematology Authors: Evgeniya V. Dolgova, Ekaterina Ya Shevela, Tamara V. Tyrinova, Alexandra M. Minkevich, Anastasia S. Proskurina, Ekaterina A. Potter, Konstantin E. Orishchenko, Evgeniy L. Zavjalov, Sergey I. Bayborodin, Valeriy P. Nikolin, Nelly A. Popova, Natalia V. Pron Tags: Original Study Source Type: research

Non-adherent spheres with multiple myeloma surface markers contain cells that contribute to the sphere formation and are capable of internalizing extracellular double-stranded DNA
We present phenotypic analysis of free-floating spheres derived from the bone marrow clonogenic aspirate of a multiple myeloma patient. Besides CD73/CD20+/CD45+/CD19dim B cells, these spheres encompass a special subpopulation of cells that can natively internalize extracellular double-stranded DNA and which contribute to the colony assembly. Various cell types found in the free-floating spheres communicate with each other by secreting distinct sets of cytokines. These spheres are capable of forming xenotrasplants upon grafting to immunodeficient NOD/SCID mice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 22, 2016 Category: Hematology Authors: Evgeniya V. Dolgova, Ekaterina Ya Shevela, Tamara V. Tyrinova, Alexandra M. Minkevich, Anastasia S. Proskurina, Ekaterina A. Potter, Konstantin E. Orishchenko, Evgeniy L. Zavjalov, Sergey I. Bayborodin, Valeriy P. Nikolin, Nelly A. Popova, Natalia V. Pron Tags: Original Study Source Type: research

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment of patients with chronic myelogenous leukemia (CML). Given the impressive and sustained response to TKI therapy that the majority of treated patients with CML enjoy, recent studies have explored the potential to achieve treatment-free remission in select patients, which may allow these patients to escape the adverse clinical and financial effects associated with life-long TKI therapy. The results of multiple prospective trials have demonstrated that patients who maintain a deep molecular response for at least 2 years with TKI treatment m...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2016 Category: Hematology Authors: Sheena Bhalla, Douglas Tremblay, John Mascarenhas Tags: Review Source Type: research

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment of patients with chronic myelogenous leukemia (CML). Given the impressive and sustained response to TKI therapy the majority of treated CML patients enjoy, recent studies have explored the potential to achieve treatment free remission (TFR) in select patients, which may allow these patients to escape the adverse clinical and financial effects associated with life-long TKI therapy. The results of multiple prospective trials have demonstrated that patients who maintain a deep molecular response for at least two years with TKI treatment may...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2016 Category: Hematology Authors: S. Bhalla, D. Tremblay, J. Mascarenhas Tags: Review Article Source Type: research

Revised International Staging System Applied to Real World Multiple Myeloma Patients
Recently, the Revised International Staging System (RISS) was introduced for clinical use and is being adopted by the International Myeloma Working Group. The RISS was developed using data from patients enrolled in clinical trials. To assess the effect of RISS in real world patients, we studied 381 patients with newly diagnosed multiple myeloma and confirmed the role of RISS in unselected nonclinical trial patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Victor H. Jimenez-Zepeda, Peter Duggan, Paola Neri, Fariborz Rashid-Kolvear, Jason Tay, Nizar J. Bahlis Tags: Original Study Source Type: research

Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged> 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients   (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Ja Min Byun, Jeong-Ok Lee, Beodeul Kang, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Soo-Mee Bang, Jong Seok Lee Tags: Original Study Source Type: research

Canonical Wnt/ β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis
Activation of the canonical wingless-related integration site (Wnt)/ β-catenin signaling pathway is associated with malignant transformation, development of fibrosis, and angiogenesis. We analyzed β-catenin mRNA expression in bone marrow of 29 patients with primary (PMF), 4 with secondary (SMF) myelofibrosis, and 16 control participants using quantitative real-time polymerase chain reaction (qRT PCR). β-Catenin expression is increased in PMF and SMF and might potentiate anemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Marko Lucijanic, Ana Livun, Cedna Tomasovic-Loncaric, Tajana Stoos-Veic, Vlatko Pejsa, Ozren Jaksic, Zeljko Prka, Rajko Kusec Tags: Original Study Source Type: research

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia
The outcome of patients with acute lymphoblastic leukemia relapsing after first allogeneic hematopoietic cell transplantation remains poor. A second transplant is a potential curative option for a subset of patients. Patients with relapse within the first year after allogeneic hematopoietic cell transplantation should preferably be enrolled in a clinical trial of novel therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Monzr M. Al Malki, Ibrahim Aldoss, Tracey Stiller, Ryotaro Nakamura, David S. Snyder, Stephen J. Forman, Vinod Pullarkat Tags: Original Study Source Type: research

Vaccination in Multiple Myeloma: Review of Current Literature
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of pati...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Andinet Alemu, John O. Richards, Martin K. Oaks, Michael A. Thompson Tags: Review Source Type: research